

**APPENDIX A - SPECIFICATION/CLAIM AMENDMENTS INCLUDING NOTATIONS
TO INDICATE CHANGES MADE**

Serial No.: 09/978,343
Docket No. 110.00280103

Amendments to the following are indicated by underlining what has been added and bracketeting what has been deleted.

In the Claims

For convenience, all pending claims are shown below.

28. [Amended] An isolated and purified antibody to a *Candida albicans* integrin-like protein,[which] wherein the protein has an amino acid sequence having SEQ ID NO:2, and wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells.
29. [Amended] The antibody of claim 28 wherein the antibody is monoclonal or[,] polyclonal[, or combinations thereof].
30. The antibody of claim 28 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 30 percent.
31. [Amended] The antibody of claim [30] 28 whercin the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 50 percent.
32. [Amended] An isolated and purified antibody to a polypeptide[which has an amino acid sequence having], wherein the polypeptide consists of SEQ ID NO:3.
33. [Amended] The antibody of claim 32 wherein the antibody is monoclonal[,] or polyclonal[, or combinations thereof].
34. [Amended] [The antibody of claim 32] An isolated and purified antibody to a polypeptide, wherein the polypeptide has the amino acid sequence of SEQ ID NO:3, and

Appendix A

Serial No. 09/978,343

Filed: October 15, 2001

Title: CANDIDA ALBICANS GENE, INTEGRIN-LIKE PROTEIN, ANTIBODIES, AND METHODS OF USE

Page A-2

wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells.

35. [Amended] The antibody of claim 34 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about [50] 30 percent.
36. [Amended] An isolated and purified antibody to a peptide [having] consisting of an amino acid sequence selected from the group consisting of:
 - (a) YLS PTN NNN SKN VSD MDL HLQ NL (SEQ ID NO:4);
 - (b) DWK LED SND GDR EDN DDI SRF EK (SEQ ID NO:5);
 - (c) SKS ANT VRG DDD GLA SA (SEQ ID NO:6);
 - (d) DHL DSF DRS YNH TEQ SI (SEQ ID NO:7); and
 - (e) WIQ NLQ EII YRN RFR RQ (SEQ ID NO:8).
37. [Amended] The antibody of claim 36 wherein the antibody is monoclonal[,] or polyclonal[, or combinations thereof].
38. [Amended] [The] An isolated and purified antibody [of claim 36] to a peptide having an amino acid sequence selected from the group consisting of:
 - (a) YLS PTN NNN SKN VSD MDL HLQ NL (SEQ ID NO:4);
 - (b) DWK LED SND GDR EDN DDI SRF EK (SEQ ID NO:5);
 - (c) SKS ANT VRG DDD GLA SA (SEQ ID NO:6);
 - (d) DHL DSF DRS YNH TEQ SI (SEQ ID NO:7); and
 - (e) WIQ NLQ EII YRN RFR RQ (SEQ ID NO:8), wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells.
39. [Amended] The antibody of claim 38 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about [50] 30 percent.

Appendix A**Page A-3**

Serial No. 09/978,343

Filed: October 15, 2001

Title: CANDIDA ALBICANS GENE, INTEGRIN-LIKE PROTEIN, ANTIBODIES, AND METHODS OF USE

40. [Amended] An isolated and purified antibody to a [*Candida albicans* peptide] polypeptide with integrin-like motifs encoded by a polynucleotide that hybridizes to DNA complementary to DNA having SEQ ID NO:1 under stringency conditions of hybridization in buffer containing 5x SSC, 5x Denhardt's, 0.5% SDS, 1 mg salmon sperm/25 mls of hybridization solution incubated at 65°C overnight, followed by high stringency washing with 0.2x SSC/0.1% SDS at 65°C, wherein the polypeptide with integrin-like motifs contains an I domain, two EF-hand divalent cation binding sites, a sequence sufficient to form a transmembrane domain, an internal RGD tripeptide, and a carboxy-terminal sequence having a single tyrosine residue, and wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells.
41. [Amended] The antibody of claim 40 wherein the [*Candida albicans* peptide with integrin-like motifs contains an I domain, two EF-hand divalent cation binding sites, a sequence sufficient to form a transmembrane domain, an internal RGD tripeptide, and a carboxy-terminal sequence having a single tyrosine residue] polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8.
42. [Amended] The antibody of claim 40 wherein the antibody is monoclonal[,] or polyclonal[, or combinations thereof].
43. The antibody of claim 40 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 30 percent.
44. [Amended] The antibody of claim [43] 40 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 50 percent.
45. [Amended] [The] An isolated and purified antibody [of claim 40 wherein the] to a *Candida albicans* [peptide] polypeptide [with integrin-like motifs is] encoded by a

Appendix A

Serial No. 09/978,343

Filed: October 15, 2001

Title: CANDIDA ALBICANS GENE, INTEGRIN-LIKE PROTEIN, ANTIBODIES, AND METHODS OF USE

Page A-4

polynucleotide having SEQ ID NO:1[.] , wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells.

46. [Amended] [An isolated and purified] The antibody of claim 28 [to a *Candida albicans* peptide with integrin-like motifs], wherein the antibody blocks adhesion to epithelial and/or endothelial cells by *Candida albicans* [peptide is] selected from [different] a morphological stage[s] of *Candida albicans* development [consisting] selected from the group consisting of blastospores, germ tubes, and hyphae[, and wherein the antibody blocks *Candida albicans* peptide adhesion to epithelial cells].
47. [Amended] The antibody of claim [46] 34 wherein the antibody blocks *Candida albicans* epithelial cell adhesion by at least about [30] 50 percent.
48. [Delete] The isolated and purified antibody of claim 46 wherein the *Candida albicans* peptide with integrin-like motifs contains an I domain, two EF-hand divalent cation binding sites, a sequence sufficient to form a transmembrane domain, an internal RGD tripeptide, and a carboxy-terminal sequence having a single tyrosine residue.
49. [New] The antibody of claim 32 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells.
50. [New] The antibody of claim 32 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 30 percent.
51. [New] The antibody of claim 32 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 50 percent.
52. [New] The antibody of claim 36 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells.

Appendix A

Serial No. 09/978,343

Filed: October 15, 2001

Title: CANDIDA ALBICANS GENE, INTEGRIN-LIKE PROTEIN, ANTIBODIES, AND METHODS OF USE

Page A-5

53. [New] The antibody of claim 36 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 30 percent.
54. [New] The antibody of claim 36 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 50 percent.
55. [New] The antibody of claim 38 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 50 percent.
56. [New] The antibody of claim 45 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 30 percent.
57. [New] The antibody of claim 45 wherein the antibody blocks *Candida albicans* adhesion to epithelial and/or endothelial cells by at least about 50 percent.
58. [New] The antibody of claim 34 wherein the antibody is monoclonal or polyclonal.
59. [New] The antibody of claim 38 wherein the antibody is monoclonal or polyclonal.
60. [New] The antibody of claim 45 wherein the antibody is monoclonal or polyclonal.
61. [New] The antibody of claim 32 wherein the antibody blocks adhesion to epithelial and/or endothelial cells by *Candida albicans* selected from a morphological stage of *Candida albicans* development selected from the group consisting of blastospores, germ tubes, and hyphae.
62. [New] The antibody of claim 34 wherein the antibody blocks adhesion to epithelial and/or endothelial cells by *Candida albicans* selected from a morphological stage of

Appendix A

Serial No. 09/978,343

Filed: October 15, 2001

Title: CANDIDA ALBICANS GENE, INTEGRIN-LIKE PROTEIN, ANTIBODIES, AND METHODS OF USE***Page A-6***

Candida albicans development selected from the group consisting of blastospores, germ tubes, and hyphae.

63. [New] The antibody of claim 36 wherein the antibody blocks adhesion to epithelial and/or endothelial cells by *Candida albicans* selected from a morphological stage of *Candida albicans* development selected from the group consisting of blastospores, germ tubes, and hyphae.
64. [New] The antibody of claim 38 wherein the antibody blocks adhesion to epithelial and/or endothelial cells by *Candida albicans* selected from a morphological stage of *Candida albicans* development selected from the group consisting of blastospores, germ tubes, and hyphae.
65. [New] The antibody of claim 40 wherein the antibody blocks adhesion to epithelial and/or endothelial cells by *Candida albicans* selected from a morphological stage of *Candida albicans* development selected from the group consisting of blastospores, germ tubes, and hyphae.
66. [New] The antibody of claim 45 wherein the antibody blocks adhesion to epithelial and/or endothelial cells by *Candida albicans* selected from a morphological stage of *Candida albicans* development selected from the group consisting of blastospores, germ tubes, and hyphae.